Schnitzler Syndrome

Schnitzler's SyndromeSchS

Rare acquired autoinflammatory disorder characterised by chronic urticarial rash with monoclonal IgM gammopathy and systemic inflammation. First described in 1972 by Liliane Schnitzler, the syndrome involves dysregulated IL-1β signalling driving fever, bone pain, arthralgia, and elevated inflammatory markers.

748 reported casesDiscovered 19720

Understanding status

Pathophysiology
Partially understood
55%
Treatment
Effective options available
80%
Genetic basis
Under investigation
35%

Epidemiology

Total cases
748
Mean onset
53 years
Onset range
13–71 years
Sex ratio (M:F)
1.76:1
Diagnostic delay
~5 years
Discovered
1972 (Liliane Schnitzler)
Prevalence
<1/1,000,000
Classification
Autoinflammatory, Hematologic

Cardinal features

8 key symptoms and signs

FeatureFrequencyCategorySources
Chronic urticarial rash
Non-pruritic or mildly pruritic wheals, often worse in evening. Individual lesions last <24 hours. Neutrophilic dermal infiltrate on biopsy.
100%dermatologic
Monoclonal IgM gammopathy
Obligate diagnostic criterion. IgM-kappa in ~94% of cases. M-spike often low (median 0.6 g/dL). SPEP alone may miss it in 51% — immunofixation required.
100%laboratory
Recurrent fever
Intermittent fever >38°C, often in evening. Resolves within hours of anakinra.
85%systemic
Bone pain
Predominantly distal femora and proximal tibiae ('hot knees'). Osteosclerotic lesions on imaging in 64%.
70%musculoskeletal
Arthralgia
Joint pain without destructive arthropathy. Large joints most commonly affected.
75%musculoskeletal
Fatigue
Often severe and debilitating. Correlates with inflammatory marker levels.
80%systemic
Elevated CRP
Consistently elevated C-reactive protein reflecting systemic inflammation. Normalizes rapidly with IL-1 blockade.
95%laboratory
Elevated ESR
Erythrocyte sedimentation rate >20 mm/h. Minor criterion in Lipsker criteria.
90%laboratory

Hypothesis tracker

Competing explanations ranked by evidence weight

#1leading
Shared MYD88/NF-κB mechanism drives both autoinflammation and B-cell clonality
48 studies·pathogenesis
55
evidence
#2competing
Independent parallel processes: inflammasome dysregulation and MGUS are separate consequences of an upstream event
30 studies·pathogenesis
35
evidence
#3competing
IL-1 blockade may prevent lymphoproliferative transformation to Waldenström's
12 studies·treatment
30
evidence
#4emerging
Schnitzler syndrome is a spectrum, not a single disease
15 studies·pathogenesis
30
evidence
#5weakening
Monoclonal IgM directly triggers inflammasome activation (autoantibody model)
22 studies·pathogenesis
25
evidence
#6emerging
NLRP3 somatic mosaicism is the primary driver in a subset of patients
8 studies·genetics
20
evidence
#7emerging
Pyrin-inflammasome dysfunction (MEFV variants) contributes to pathogenesis
4 studies·genetics
15
evidence

Open questions

1
What is the relationship between the monoclonal gammopathy and the autoinflammation?
Three competing hypotheses exist. MYD88 L265P is the strongest candidate for a shared mechanism but is absent in ~70% of patients.
2
What triggers the initial inflammasome dysregulation?
No consistent genetic mutation identified. Environmental triggers? Stochastic cellular events? Epigenetic dysregulation?
3
Does IL-1 blockade prevent lymphoproliferative transformation?
Suggestive data from the French cohort but IL-1 therapy does not alter monoclonal component levels. Needs long-term prospective studies.
4
Can ibrutinib address both the inflammatory and gammopathy components simultaneously?
Only agent shown to reduce monoclonal protein AND control symptoms. Very limited data. Needs prospective trials.
5
Is Schnitzler syndrome truly a single disease or a spectrum?
Growing recognition of IgG variants, Schnitzler-like syndromes without gammopathy, and molecular subtypes.
6
What is the role of newly identified genes (MEFV, F2)?
MEFV variants found in some patients (2024-2025). MEFV encodes pyrin (inflammasome inhibitor). Significance uncertain.

Recent updates

genetic finding
Novel MEFV/F2 gene variants in 748th Schnitzler case
Case report from Hungary identified novel MEFV gene variant c.2084A>G and F2 gene variant. Strengthens pyrin-inflammasome hypothesis.
treatment update
Bortezomib (proteasome inhibitor) case report published
Novel use of bortezomib in a patient without detectable serum IL-1β and absent MYD88 L265P.
new research
First Schnitzler syndrome cases reported from Iran
Aminianfar et al. (2025) reported the first cases from Iran, highlighting challenges without access to IL-1 inhibitors.
Get research updates
Weekly digest · Unsubscribe anytime
Schnitzler Syndrome | Kipine